XV SDDN meeting 2023, Barcelona

On November 20th and 21st, some members of the Welab’s team attended the XV Spanish Drug Discovery Network (SDDN) meeting,…

A new JMedChem publication from…

Discovery of WLB-89462, a New Drug-like and Highly Selective σ2 Receptor Ligand with Neuroprotective Properties”, in the Journal of Medicinal…

Fundación MEDINA and WeLab Barcelona

Fundación Medina and WeLab Barcelona have signed a collaboration agreement that allows combining experience and resources for the discovery and…

New Sigma-1 receptor-BiP biosensor

Scientists from the Pathology and Experimental Therapeutics Dept., Facultat de Medicina i Ciències de la Salut of the Universitat de…

Taros – Welab collaboration agreement

We are proud to announce that Welab Barcelona, the drug discovery & development platform of Leitat, has signed a strategic…

Pharmacelera-Welab partnership agreement

Pharmacelera, the leading provider of computational tools for hit discovery, and Welab, the leading drug discovery and development platform is…

Where does our logo come…

https://www.welabbarcelona.com/wp-content/uploads/2023/06/Welab-logo.mp4

Spirify – Welab Barcelona research…

WeLab Barcelona has reached an agreement with Spirify Pharma for a research collaboration on characterization of Spirify’s proprietary analogs of…

Carcinogenicity studies of cizolirtine, a…

Check out the new Welab’s publication on toxicological profile of cizolirtine. Results from two-year rodent oral carcinogenicity studies of cizolirtine,…